Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurasidone Hydrochloride

FDA-approved product (tablet, oral), marketed as Latuda, Lurasidone Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lurasidone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bipolar disorder
  • Bipolar I disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurasidone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurasidone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy

    NCT07781293 · start 2026-09-28

    Registered record
    Registry ID
    NCT07781293
    Conditions
    Major Depressive Disorder (MDD); Major Depressive Disorder With Psychotic Features
    Interventions
    Lurasidone; Placebo; Background Antidepressant Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09-28
    Completion
    2027-10
    Enrolment
    364

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD); Major Depressive Disorder With Psychotic Features
    InterventionLurasidone; Placebo; Background Antidepressant Therapy
    PhasePhase 3
    Registry statusNot yet recruiting

  • Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

    NCT07785102 · start 2026-09-01

    Registered record
    Registry ID
    NCT07785102
    Conditions
    Major Depression
    Interventions
    TMS; NRX-101
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2027-03-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionTMS; NRX-101
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Sequential Multiple Assignment Randomized Trial for Bipolar Depression

    NCT06433635 · start 2024-10-01

    Registered record
    Registry ID
    NCT06433635
    Conditions
    Bipolar I Disorder; Depression
    Interventions
    Cariprazine; Aripiprazole/Escitalopram combination; Quetiapine; Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-10-01
    Completion
    2030-02-28
    Enrolment
    2,726

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder; Depression
    InterventionCariprazine; Aripiprazole/Escitalopram combination; Quetiapine; Lurasidone
    PhasePhase 4
    Registry statusActive not recruiting

  • An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

    NCT05741502 · start 2023-08-16

    Registered record
    Registry ID
    NCT05741502
    Conditions
    Treatment-resistant Schizophrenia
    Interventions
    Clozapine; Antipsychotics,Other (non-Clozapine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-08-16
    Completion
    2026-01-23
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment-resistant Schizophrenia
    InterventionClozapine; Antipsychotics,Other (non-Clozapine)
    PhasePhase 4
    Registry statusTerminated

  • Lurasidone Non-Interventional Study in Schizophrenia Patients

    NCT06527885 · start 2022-10-21

    Registered record
    Registry ID
    NCT06527885
    Conditions
    Schizophrenia
    Interventions
    Lurasidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-21
    Completion
    2023-09-12
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone
    PhaseNot recorded
    Registry statusCompleted

  • Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    NCT04312503 · start 2020-07-13

    Registered record
    Registry ID
    NCT04312503
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2022-10-31
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    PhaseNot recorded
    Registry statusCompleted

  • NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

    NCT03396068 · start 2019-12-01

    Registered record
    Registry ID
    NCT03396068
    Conditions
    Bipolar Depression; Suicidal Ideation
    Interventions
    NRX-101; Lurasidone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-12-01
    Completion
    2024-12-31
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression; Suicidal Ideation
    InterventionNRX-101; Lurasidone HCl
    PhasePhase 3
    Registry statusUnknown

  • A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

    NCT03557931 · start 2018-07-13

    Registered record
    Registry ID
    NCT03557931
    Conditions
    Schizophrenia
    Interventions
    ASP4345; placebo; risperidone; quetiapine; olanzapine; ziprasidone; aripiprazole; brexpiprazole; paliperidone; lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-13
    Completion
    2019-10-21
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionASP4345; placebo; risperidone; quetiapine +6 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

    NCT03627195 · start 2018-06-07

    Registered record
    Registry ID
    NCT03627195
    Conditions
    Schizophrenia
    Interventions
    DSP-1349M; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-07
    Completion
    2019-03-29
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionDSP-1349M; placebo
    PhasePhase 1
    Registry statusCompleted

  • Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia

    NCT03304457 · start 2017-08-25

    Registered record
    Registry ID
    NCT03304457
    Conditions
    Schizophrenia
    Interventions
    Olanzapine; Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-08-25
    Completion
    2018-03-25
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOlanzapine; Lurasidone
    PhasePhase 4
    Registry statusCompleted

  • Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

    NCT02731612 · start 2017-05-08

    Registered record
    Registry ID
    NCT02731612
    Conditions
    Bipolar Disorder
    Interventions
    lurasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-05-08
    Completion
    2024-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    Interventionlurasidone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

    NCT01932541 · start 2017-01

    Registered record
    Registry ID
    NCT01932541
    Conditions
    Mania; Bipolar I; Bipolar II; Bipolar Spectrum Disorder; Bipolar Disorder
    Interventions
    Latuda (Lurasidone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-01
    Completion
    2018-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMania; Bipolar I; Bipolar II; Bipolar Spectrum Disorder +1 more
    InterventionLatuda (Lurasidone)
    PhasePhase 4
    Registry statusWithdrawn

  • Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

    NCT02893371 · start 2016-09

    Registered record
    Registry ID
    NCT02893371
    Conditions
    Bipolar Disorder
    Interventions
    Lithium Carbonate; Lamotrigine; Valproic Acid; Oxcarbazepine; Carbamazepine; Ziprasidone; Risperidone; Quetiapine; Olanzapine; Aripiprazole; Fluoxetine / Olanzapine; Haloperidol; Perphenazine; Clozapine; Asenapine; Lurasidone; Paliperidone; Mirtazapine; Bupropion; Desvenlafaxine; Duloxetine; Venlafaxine; Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Sertraline; Vilazodone; Doxepin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-09
    Completion
    2019-06-30
    Enrolment
    1,037,352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionLithium Carbonate; Lamotrigine; Valproic Acid; Oxcarbazepine +26 more
    PhaseNot recorded
    Registry statusTerminated

  • Biosignatures of Latuda for Bipolar Depression

    NCT02239094 · start 2015-01

    Registered record
    Registry ID
    NCT02239094
    Conditions
    Bipolar Depression
    Interventions
    Lurasidone (Latuda)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Depression
    InterventionLurasidone (Latuda)
    PhaseNot applicable
    Registry statusCompleted

  • Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

    NCT02282085 · start 2014-12

    Registered record
    Registry ID
    NCT02282085
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole Once-Monthly; Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-12
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole Once-Monthly; Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
    PhasePhase 4
    Registry statusUnknown